Systemic Autoimmune Diseases
8
2
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions
Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases
Risk Factors for Postpartum Hemorrhage
Prophylactic Tranexamic Acid Reduces Postpartum Hemorrhage
A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases:
Auto-immune Diseases and Quality of Life